Committed, Solid Leadership
President and Executive Director
- Robert F. (Bobby) Anderson
Board of Trustees
Chairman
- Raymond J. Khoury
Vice Chairman
- Mr. Kim D. Wheless
Members
- George S. Conklin
- Beppino C. Giovanella, PhD
- John E. Hine
- Peter D. de Ipolyi, MD
- Donna S. Lewis
- A. Gordon Findlay, Jr.
- John A. Gillean, MD
- Michael A. Meagher
- Ethan A. Natelson, MD
- John S. Stehlin, Jr., MD
- Nancy B. White
- Sister Rosanne Popp, MD
- Michael W. Ross, Ph.D.
- Thomas C. Royer, MD
- Lin R. Mills Smolensky
News
In Mice, Cancer Drug Shows Effect on Alzheimer's Symptoms
The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.
Genetic Breakthrough for Brain Cancer in Children
An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.
Skin Cancer Drug Approved
Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer.
Our Team
“I think it has been too easy to overlook what a progressive physician Dr. John Stehlin was, and how pivotal he was for the humane treatment of individuals with cancer. He changed the cancer landscape forever, and his work continues with the research the CHRISTUS Stehlin Foundation is doing today.”
Dr. Peter de Ipolyi,
Surgical Oncologist
Stay Connected
Affiliates and Resources
